|
| 37038005 | Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. | Nat Cancer | 2023 |
| 36250965 | COVID-related transaminitis confounding toxicity attribution in a child with brain tumour on targeted therapy. | Pediatric Blood and Cancer | 2023 |
| 37606641 | Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study. | | 2023 |
| 37857712 | AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial. | Nat Med | 2023 |
| 37012551 | Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. | Nat Med | 2023 |
| 37441939 | Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2023 |
| 37178647 | Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. | Eur J Cancer | 2023 |
| 34933802 | Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. | Eur J Cancer | 2022 |
| 35395680 | Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). | Neuro Oncol | 2022 |
| 36335782 | Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 36467471 | Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations. | Frontiers in Pediatrics | 2022 |
| 34737188 | DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. | Cancer Discovery | 2022 |
| 35290915 | ACCELERATE - Five years accelerating cancer drug development for children and adolescents. | Eur J Cancer | 2022 |
| 34840026 | Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 34536944 | Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. | Eur J Cancer | 2021 |
| 33860230 | In-circuit high-frequency jet ventilation to reduce organ motion in a child undergoing sarcoma ablation. | Anesthesia Reports | 2021 |
| 34169282 | Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. | Neurooncol Adv | 2021 |
| 34168987 | Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. | Front Oncol | 2021 |
| 33900873 | High grade gliomas in young children: The South Thames Neuro-Oncology unit experience and recent advances in molecular biology and targeted therapies. | Pediatric Hematology and Oncology | 2021 |
| 34157616 | Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. | European Journal of Cancer | 2021 |
| 32999470 | Reply to 'Comment on "Tumour-agnostic drugs in paediatric cancers"'. | British Journal of Cancer | 2021 |
| 34780709 | Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. | Lancet Oncol | 2021 |
| 34543871 | First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. | Eur J Cancer | 2021 |
| 34649088 | Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma. | European Journal of Cancer | 2021 |
| 33129040 | Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. | Eur J Cancer | 2020 |
| 32375866 | Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. | Journal of Experimental and Clinical Cancer Research | 2020 |
| 32421361 | How to address challenges and opportunities in pediatric cancer drug development? | Expert Opinion on Drug Discovery | 2020 |
| 32183592 | Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective. | Pediatric Hematology and Oncology | 2020 |
| 32238360 | Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. | Cancer Discov | 2020 |
| 31617673 | Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies. | Pediatric Blood and Cancer | 2020 |
| 32161367 | Tumour-agnostic drugs in paediatric cancers. | British Journal of Cancer | 2020 |
| 31986450 | ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. | Eur J Cancer | 2020 |
| 31812554 | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. | Lancet Oncol | 2020 |
| 32992153 | Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2020 |
| 32653773 | Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. | Eur J Cancer | 2020 |
| 32688206 | Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2020 |
| 30772656 | ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. | Eur J Cancer | 2019 |
| 30877107 | MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. | Cancer Res | 2019 |
| 31543384 | A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. | Eur J Cancer | 2019 |
| 31493701 | High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. | Leukemia Research | 2019 |
| 30978130 | Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. | Pediatric Hematology and Oncology | 2019 |
| 29236237 | Outcome of children and adolescents with central nervous system tumors in phase I trials. | J Neurooncol | 2018 |
| 29967352 | Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. | Nat Med | 2018 |
| 29351570 | Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. | Ann Oncol | 2018 |
| 29508745 | 10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers. | Lancet Oncology, The | 2018 |
| 27615273 | Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. | Pediatric Blood and Cancer | 2017 |
| 28604107 | Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. | Expert Opin Drug Discov | 2017 |
| 28677575 | From class waivers to precision medicine in paediatric oncology. | Lancet Oncol | 2017 |
| 28704425 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. | PLoS One | 2017 |